|
Fernandez O, Alvarez-Cermeno JC, Arroyo R, Brieva L, Calles-Hernandez MC, Casanova-Estruch B, Comabella M, Garcia-Merino JA, Ginestal R, Izquierdo G, Meca-Lallana JE, Mendibe-Bilbao MM, Montalban X, Munoz-Garcia D, Olascoaga J, Oliva-Nacarino P, Oreja-Guevara C, Ramio-Torrenta L, Romero-Pinel L, Rodriguez-Antiguedad A, Saiz A, Tintore M, Grupo Post-Ectrims GP. Review of the novelties from the 2014 ECTRIMS-ACTRIMS Joint Congress, presented at the 7th Post-ECTRIMS Meeting (II). Rev Neurol. 2015 Sep 16;61(6):271-83. English, Spanish. PubMed PMID: 26350778.
AÑO: 2015; IF: 0.684
|
26350778
|
Fernandez O, Alvarez-Cermeno JC, Arroyo R, Brieva L, Calles-Hernandez MC, Casanova-Estruch B, Comabella M, Garcia-Merino JA, Ginestal R, Izquierdo G, Meca-Lallana JE, Mendibe-Bilbao MM, Montalban X, Munoz-Garcia D, Olascoaga J, Oliva-Nacarino P, Oreja-Guevara C, Ramio-Torrenta L, Romero-Pinel L, Rodriguez-Antiguedad A, Saiz A, Tintore M, Grupo Post-Ectrims GP. [Review of the novelties from the 2014 ECTRIMS-ACTRIMS Joint Congress, presented at the 7th Post-ECTRIMS meeting (I)]. Rev Neurol. 2015 Sep 1;61(5):215-24. Spanish. PubMed PMID: 26308843.
AÑO: 2015; IF: 0.684
|
|
Saiz A, Mora S, Blanco J; en representacion de los investigadores del estudio COMPLIANCE. Therapeutic compliance of first line disease-modifying therapies in patients with multiple sclerosis. COMPLIANCE Study. Neurologia. 2015 May;30(4):214-22. doi: 10.1016/j.nrl.2013.12.008. Epub 2014 Jan 28. English, Spanish. PubMed PMID: 24484756.
AÑO: 2015; IF: 3.9
|
|
Muntéis Olivas E, Navarro Mascarell G, Meca Lallana J, Maestre Martínez A, Pérez Sempere Á, Gracia Gil J, Pato Pato A. Cultural adaptation and validation of a peninsular Spanish version of the MSTCQ(©) (Multiple Sclerosis Treatment Concerns Questionnaire). Neurologia. 2015 Feb 16. pii: S0213-4853(15)00006-7. doi: 10.1016/j.nrl.2014.12.011. [Epub ahead of print] English, Spanish. PubMed PMID: 25697827.
AÑO: 2015; IF: 1.79
|
|
Mäurer M, Van Wijmeersch B, de Seze J, Meca-Lallana J, Bozzi S, Vermersch P. Significant and Meaningful Improvement in Treatment Satisfaction with Teriflunomide Versus Subcutaneous IFNB-1A in Patients with Relapsing MS Results from Tenere. Value Health. 2014 Nov;17(7):A403. doi: 10.1016/j.jval.2014.08.927. Epub 2014 Oct 26. PubMed PMID: 27200967.
AÑO: 2014; IF: 5.494
|